Literature DB >> 17266590

Controlled delivery of peptides and proteins.

I Tuncer Degim1, Nevin Celebi.   

Abstract

The final aim/target of Pharmaceutical Sciences is to design successful dosage forms for effective therapy, considering individual patient needs and compliance. Development of new drug entities, particularly using peptides and proteins, is growing in importance and attracting increased interest, as they are specifically effective at a comparably low dose. These very potent and specific peptides and proteins can now be produced in large quantities due to increased knowledge and advancements in biotechnological and pharmaceutical applications. A number of peptide and protein products are now available on the market, and numerous studies investigating them have been published in the literature. Although many peptide/protein like products are generally designed for parenteral administration, some other noninvasive routes have also been used. For example, desmopressin is delivered nasally and deoxyribonuclease by inhalation. Although peptides and proteins are generally orally inactive, cyclosporine is an exception. In order to design and develop long-acting, more effective peptide/protein drugs, the controlled release mechanisms and effective parameters need to be understood and clarified. Therefore, we review herein various peptide/protein delivery systems, including biodegradable and nondegradable microspheres, microcapsules, nanocapsules, injectable implants, diffusion-controlled hydrogels and other hydrophilic systems, microemulsions and multiple emulsions, and the use of iontophoresis or electroporation, and discuss the results of recent researches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266590     DOI: 10.2174/138161207779313795

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  15 in total

Review 1.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 2.  Long-term delivery of protein therapeutics.

Authors:  Ravi Vaishya; Varun Khurana; Sulabh Patel; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2014-09-24       Impact factor: 6.648

3.  Biocompatibility and bioactivity of an FGF-loaded microsphere-based bilayer delivery system.

Authors:  Dong Hwa Kim; Julianne Huegel; Brittany L Taylor; Courtney A Nuss; Stephanie N Weiss; Louis J Soslowsky; Robert L Mauck; Andrew F Kuntz
Journal:  Acta Biomater       Date:  2020-05-16       Impact factor: 8.947

4.  Natural and Genetically Engineered Proteins for Tissue Engineering.

Authors:  Sílvia Gomes; Isabel B Leonor; João F Mano; Rui L Reis; David L Kaplan
Journal:  Prog Polym Sci       Date:  2012-01-01       Impact factor: 29.190

Review 5.  The benefits and challenges associated with the use of drug delivery systems in cancer therapy.

Authors:  Edna Cukierman; David R Khan
Journal:  Biochem Pharmacol       Date:  2010-04-22       Impact factor: 5.858

Review 6.  Hyaluronic Acid-Based Nanomaterials as a New Approach to the Treatment and Prevention of Bacterial Infections.

Authors:  Reza Alipoor; Mohammad Ayan; Michael R Hamblin; Reza Ranjbar; Somaye Rashki
Journal:  Front Bioeng Biotechnol       Date:  2022-06-08

7.  Pulmonary drug delivery strategies: A concise, systematic review.

Authors:  J S Patil; S Sarasija
Journal:  Lung India       Date:  2012-01

8.  Encapsulation of Phaseolus lunatus Protein Hydrolysate with Angiotensin-Converting Enzyme Inhibitory Activity.

Authors:  Jorge Carlos Ruiz Ruiz; Maira Rubí Segura Campos; David Abram Betancur Ancona; Luis Antonio Chel Guerrero
Journal:  ISRN Biotechnol       Date:  2013-09-24

Review 9.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

10.  Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.

Authors:  Michael Hrynyk; Jordon P Ellis; Fiona Haxho; Stephanie Allison; Joseph Am Steele; Samar Abdulkhalek; Ronald J Neufeld; Myron R Szewczuk
Journal:  Drug Des Devel Ther       Date:  2015-08-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.